SCHEMBL3099651

SCHEMBL3099651

CC(Oc1ccc([N+](=O)[O-])cc1F)c1c(Cl)ccc(Cl)c1Cl

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.42
KMT2A Q03164 4/20 0.41
MET P08581 6/20 0.41
HSPB1 P04792 3/20 0.40
S1PR4 O95977 1/20 0.40
MEN1 O00255 3/20 0.40
ALDH1A1 P00352 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
LMNA P02545 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
MAPT P10636 2/20 0.39
PDE7A Q13946 1/20 0.38
ALK Q9UM73 1/20 0.37
GAA P10253 1/20 0.37
XBP1 P17861 1/20 0.37
HTT P42858 1/20 0.37
RAB9A P51151 1/20 0.37
CCR6 P51684 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3093667 0.94 KMT2A (0.41) HSD17B10KMT2AMETHSPB1S1PR4
SCHEMBL3102150 0.94 MET (0.48) METALK
SCHEMBL3104420 0.89 HSPB1 (0.41) HSD17B10KMT2AHSPB1S1PR4MEN1
SCHEMBL3111405 0.86 MET (0.48) HSD17B10KMT2AMETMEN1ALDH1A1
SCHEMBL3097938 0.84 MET (0.47) METLMNAMAPTALK
SCHEMBL3099647 0.79 LMNA (0.44) HSD17B10KMT2AMETHSPB1MEN1
SCHEMBL15210001 0.78 CYP19A1 (0.54) KMT2AHSPB1S1PR4MEN1ALDH1A1
SCHEMBL3101859 0.78 MET (0.51) METALK
SCHEMBL3099307 0.77 HSPB1 (0.41) HSD17B10KMT2AMETHSPB1MEN1
SCHEMBL3109670 0.77 MET (0.50) MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188078-B2 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as C-MET inhibitors SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS SANOFI-AVENTIS (FR) 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS MET, ALK, JAK2 HSD17B10 4257/4885KMT2A 959/4885MET 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.